Maintenance rituximab in follicular non-Hodgkin lymphoma: Facts and controversies

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 770-778

  Nabhan, Chadi ^a   Smith, Sonali M ^b   Kahl, Brad S ^c  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

follicular lymphoma; immunotherapy; maintenance; maintenance rituximab; non Hodgkin lymphoma; Rituximab

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANEMIA; ARTHRALGIA; BODY WEIGHT; CACHEXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FATIGUE; FOLLICULAR LYMPHOMA; HEART DISEASE; HISTOLOGY; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG DISEASE; MAINTENANCE CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STRESS FRACTURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN;

EID: 84859988265     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.628061     Document Type: Review

References (46)

1. Rosenberg SA. Follicular lymphoma revisited. J Clin Oncol 2008;26:515-516. (Pubitemid 351264340)
2. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-8452.
3. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) signifi cantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732. (Pubitemid 41742196)
4. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-4586.
5. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-Analysis. J Natl Cancer Inst 2007;99:706-714. (Pubitemid 47078732)
6. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-Analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215-2223. (Pubitemid 46218713)
7. Baldo P, Rupolo M, Compagnoni A, et al. Interferon-Alpha for maintenance of follicular lymphoma. Cochrane Database Syst Rev 2010;(1):CD004629.
8. Steward WP, Crowther D, McWilliam LJ, et al. Maintenance chlorambucil after CVP in the management of advanced stage, lowgrade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 1988;61:441-447. (Pubitemid 18039355)
9. Hainsworth JD, Litchy S, Shaff er DW, et al. Maximizing therapeutic benefi t of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-1095. (Pubitemid 46202263)
10. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma signifi cantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416-4423. (Pubitemid 38745964)
11. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-Agent rituximab at two diff erent schedules in trial SAKK 35/98. J Clin Oncol 2010;28:4480-4484.
12. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301. (Pubitemid 44794222)
13. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-2858.
14. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a signifi cant prolongation of response duration after salvage therapy with a combination of rituximab, fl udarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008. (Pubitemid 44920177)
15. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with lowgrade non-Hodgkin lymphoma. Blood 2000;95:3052-3056. (Pubitemid 30321153)
16. Ardeshna K, Qian W, Smith P, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 2010;116(Suppl. 1): Abstract 6.
17. Kahl BS. Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). Clin Lymphoma Myeloma 2006;6:423-426.
18. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-1614.
19. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: Fi rst report of the national LymphoCare study. J Clin Oncol 2009;27:1202-1208.
20. Salles G, Seymour JF, Off ner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2011;377:42-51.
21. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-Analysis of randomized trials. J Natl Cancer Inst 2009;101:248-255.
22. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diff use large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127. (Pubitemid 46638950)
23. Morrison V, Hong F, Habermann T, et al. R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diff use large B-cell lymphoma (DLBCL) patients (pts): Long-term follow-up of Intergroup E4494/C9793. Blood 2010;116(Suppl. 1): Abstract 589.
24. Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as fi rst-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Fi nal results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): Abstract 405.
25. Hirt C, Schuler F, Dolken G. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. Semin Cancer Biol 2003;13:223-231. (Pubitemid 36581895)
26. Ladetto M, Magni M, Pagliano G, et al. Rituximab induces eff ective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006;12:1270-1276. (Pubitemid 44858257)
27. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833. (Pubitemid 28363048)
28. Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol 2003;30:9-15. (Pubitemid 36337347)
29. Hainsworth JD, Litchy S, Barton JH, et al. Single-Agent rituximab as fi rst-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-1751. (Pubitemid 46638587)
30. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001. (Pubitemid 28496709)
31. Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005;23:1096-1102. (Pubitemid 46202264)
32. Kahl B, Williams M, Hong F, et al. Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT). Blood 2007;110(Suppl. 1): Abstract 3420.
33. Taverna C, Bassi S, Hitz F, et al. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03. Blood 2010;116(Suppl. 1): Abstract 1802.
34. Kasteng F, Erlanson M, Hagberg H, et al. Cost-eff ectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol 2008;47:1029-1036.
35. Deconinck E, Miadi-Fargier H, Pen CL, et al. Cost eff ectiveness of rituximab maintenance therapy in follicular lymphoma: Long-term economic evaluation. Pharmacoeconomics 2010;28:35-46.
36. Rao A, Kelly M, Musselman M, et al. Safety, effi cacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008;50:822-825. (Pubitemid 351354792)
37. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-4840.
38. L i X, Lin Q, Dong M, et al. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma 2010;51:1678-1685.
39. Matsue K, Kimura S, Takanashi Y, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010;116:4769-4776.
40. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255-262.
41. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27: 605-611.
42. Ziakas PD, Karsaliakos P, Mylonakis E. Eff ect of prophylactic lamivudine for chemotherapy-Associated hepatitis B reactivation in lymphoma: A meta-Analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005.
43. Bermudez A, Marco F, Conde E, et al. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000;85:894-895.
44. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307-1312. (Pubitemid 47079357)
45. Herold M, Haas A, Srock S, et al. Rituximab added to fi rst-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-1992. (Pubitemid 46972781)
46. Foá R, Di Rocco A, Van Hazel G, et al. Maintenance rituximab every 2 months for 2 years is eff ective and well tolerated in patients with follicular lymphoma with both standard or rapid infusion: Updated results from the phase IIIb MAXIMA study. Blood 2010;116(Suppl. 1): Abstract 3945.